Novo Nordisk Alliance
The NOVO NORDISK RESEARCH CENTRE OXFORD (NNRCO)
Novo Nordisk Research Centre Oxford is an innovative target discovery and translational research unit with a focus on identifying novel, game-changing therapies for patients with diabetes and cardiometabolic diseases.
The centre employs advanced computational biology, state-of-the-art discovery screening technologies, genetics and human-centric cell systems to dissect pathophysiology and identify novel drug targets. The site is a fusion of the best of academia, biotech and big pharma in order to realize cutting-edge biology and start a target’s journey from bench to bedside.
The alliance between Novo Nordisk and Oxford aims to establish landmark collaborations for the advancement in research for diabetes and cardiometabolic disease with an aim to work towards innovative medicines that that make a difference in patients' lives.
Uniquely, the alliance has seen Novo Nordisk establish a presence onsite at the University of Oxford, with NNRCO employing up to 100 researchers between 2017 and 2021. These NNRCO researchers will work in new state-of-the-art laboratories in the Innovation Building on Old Road Campus, which officially opened on the 12th September 2018.
Collaborative projects have been jointly developed and co-funded via the Strategic Alliance Committee and NNRCO also participates in the training of the next generation of diabetes research scientists by co-sponsoring students. Find out more about funding from Novo Nordisk (Requires SSO).
NNRCO itself is led by Professor Bill Haynes and is composed of 4 departments Computational Biology, Discovery Technologies and Genomics and Discovery Biology and Pharmacology - Explore NNRCO Departments.
SUPPORT FOR THE ALLIANCE
The alliance is governed by a Joint Steering Committee, made up of parties from both the University of Oxford and Novo Nordisk. This joint governance structure allows for an alignment of research interests and offers an opportunity to work truly collaboratively. A collaboration committee has also been appointed that can act more swiftly to review and approve smaller collaborative opportunities.
The alliance benefits from a dedicated alliance manager, Dr Siobhan Dennis, who acts as a point of contact for both organisations and provides support for calls and projects. Please note that Dr Dennis is only able to advise Oxford University staff on collaboration and roles with Novo Nordisk, and is not able to comment on speculative applications.